Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

Completed · Phase 1

Conditions studied: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer

In brief

As a follow-on study to NCT01416038, this study is designed to identify the optimal dosage of immunotherapeutic survivin vaccine DPX-Survivac and low dose oral cyclophosphamide. The combination treatment is being evaluated in a non-randomized, multi-cohort study as post-chemotherapy treatment for patients with late-stage ovarian, fallopian tube, or peritoneal cancer.

Key facts

Study ID

NCT03332576

Run by

ImmunoVaccine Technologies, Inc. (IMV Inc.)

People needed

37

Starts

2013-08-23

Expected to finish

2019-09-09

Last updated by the study team

2021-06-18

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Winthrop University Hospital — Mineola, New York, United States
• Lenox Hill Hospital — New York, New York, United States
• Princess Margaret Cancer Centre — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.